Modern is entering clinical trials for its mRNA-based flu vaccine


Moderna first injected its mRNA vaccine against seasonal flu into a human volunteer as part of a phase 1/2 clinical study, the company announced Wednesday.

This is a very early test for new vaccine technology, aimed primarily at building a basic understanding of “safety, reactogenicity, and immunogenicity of treatment,” according to Modern version. mRNA-1010, as the vaccine is called, was created to work against the four most common strains of the virus, including, A H1N1, H3N2, influenza B Yamagata, and influenza B Victoria.

According to the World Health Organization, these strains cause between 3 and 5 million severe cases of flu each year, resulting in as many as 650,000 deaths from flu-related respiratory illnesses each year. In the United States alone, approximately 8 percent of the population suffers from the flu each winter. The company hopes this vaccine will prove more powerful than the current efficiency rate of 40 to 60 percent with conventional flu vaccines.

“We are glad that we have started this phase of the 1/2 study of mRNA-1010, our first candidate for seasonal flu against mRNA who entered the clinic. We expect our candidates for a seasonal flu vaccine to be an important component of our future combined respiratory vaccines, ”said Moderna CEO Stéphane Bancel. “Combined respiratory vaccines are an important pillar of our overall mRNA vaccine strategy. We believe that the benefits of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to respond rapidly to the evolution of respiratory viruses, such as influenza, SARS-CoV-2, and RSV. Our vision is to develop a combined mRNA vaccine so that people can get one injection each fall for high protection effectiveness against the most problematic respiratory viruses. “

This vaccine was produced using the same genomic techniques that the company used develop your treatment COVID-19 2020. The technique works by using the body’s own cells to reproduce viral DNA fragments to trigger an immune response and prepare the body for future infection. Because this method does not require the entire virus (weakened or dead), but only the skinny genetic code, mRNA vaccines can be applied to any number of deadly modern diseases, including malaria, TB – even cancer.

All products recommended by Engadget are selected by our editorial team, regardless of our parent company. Some of our stories include associated links. If you buy something through one of these links, we may earn an associated commission.

Source link


Please enter your comment!
Please enter your name here